NCI-H838Homo sapiens (Human)Cancer cell line

Also known as: NCIH838, H-838, H838

🤖 AI SummaryBased on 12 publications

Quick Overview

Human cancer cell line with potential applications in lung cancer research.

Detailed Summary

The NCI-H838 cell line is a human-derived cancer cell line that has been utilized in various cancer research studies. It is particularly noted for its role in investigating small cell lung cancer (SCLC) and has been part of studies examining genetic and molecular characteristics of cancer cells. This cell line has been used to explore the role of specific genes and pathways in cancer progression, including the RB-related gene family and the potential for targeted therapies. The cell line has also been involved in studies related to the identification of novel therapeutic targets and the evaluation of drug sensitivity in cancer treatment. While the specific tissue of origin and disease characteristics are not explicitly detailed, the cell line's utility in understanding cancer biology and developing therapeutic strategies is well-documented.

Research Applications

Small cell lung cancer researchGenetic and molecular characterization of cancer cellsIdentification of therapeutic targetsDrug sensitivity evaluation

Key Characteristics

Utilized in studies of RB-related gene familyPart of research on cancer progression pathwaysUsed in evaluating drug responses in cancer treatment
Generated on 6/17/2025

Basic Information

Database IDCVCL_1594
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age59
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000416_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Glu62Ter (c.184G>T)Homozygous-from parent cell line NCI-H838
MutationSimpleARID1Ap.Pro1876Serfs*22 (c.5625_5632del) (p.CPP1657fs) (c.5621_5628delGCCCACCA)Heterozygous-from parent cell line NCI-H838

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
8
D16S539
9,12
D18S51
12
D19S433
15.2
D21S11
32.2
D2S1338
18
D3S1358
15
D5S818
11
D7S820
9
D8S1179
13,16
FGA
22.2
Penta D
11
Penta E
5,12
TH01
7
TPOX
8,11
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system.

Bourgon R., Neve R.M.

PLoS ONE 10:E0116218-E0116218(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources